Candel Therapeutics

Did you know??CAN-2409, our investigational viral immunotherapy, is designed to help stimulate the body’s immune response against cancer. When combined with valacyclovir, it?activates the immune system that may help fight tumor cells.?? ? We're studying CAN-2409's potential to improve disease outcomes in prostate cancer?while maintaining quality of life. Stay tuned for updates later this year.?? ? Learn how CAN-2409 works: https://lnkd.in/eN7KM7Di ? #CancerTreatment #ClinicalTrials #ImmunotherapyResearch #CancerImmunotherap

For men diagnosed with localized prostate cancer, treatment decisions can be complex. While active surveillance helps avoid over-treatment in low-risk disease, many patients will still experience disease progression. At Candel, we're investigating new approaches that could potentially bridge this gap through our clinical trials in localized prostate cancer. Learn more: https://lnkd.in/evZ7S6Zv

This World Pancreatic Cancer Day, we're highlighting our phase 2 clinical trial of CAN-2409, our investigational viral immunotherapy, combined with standard of care in patients with borderline resectable pancreatic cancer.? ? Patients receiving CAN-2409 achieved estimated median overall survival of 28.8. months, with more than 70% survival at two-years, compared to 12.5 months and nearly 17% in the control group that received standard of care only. CAN-2409 works by in situ vaccination against the patient’s tumor and fundamentally changing the tumor's microarchitecture, potentially offering new hope for pancreatic cancer patients.? ? CAN-2409 previously received FDA Fast Track Designation and Orphan Drug Designation.? ? Learn more about our approach: https://lnkd.in/dGPghctu?? ? #WorldPancreaticCancerDay #CancerResearch #PancreaticCancer #ClinicalTrials?

We are attending! Paul Peter Tak, MD PhD FMedSci President and CEO, is delivering a keynote at the British Society for Immunology (BSI) Immune Therapies Summit next week in Cambridge! He'll be discussing our work on viral immunotherapy as a novel approach to inducing systemic anti-tumor immunity. We are looking forward to engaging discussions and sharing insights with colleagues. https://lnkd.in/eqDHHn4P #Immunology #CancerResearch #Biotechnology #BSIImmunoTherapies24

Candel is conducting a phase 2b clinical trial in prostate cancer to evaluate CAN-2409, our lead asset, in patients with low-to-intermediate risk disease who are undergoing active surveillance. The trial aims to assess whether CAN-2409 administration could stop disease progression. Learn more: https://lnkd.in/evZ7S6Zv #Oncology #ProstateCancer #MedicalResearch #ClinicalResearch #ClinicalTrials

Paul Peter Tak, MD PhD FMedSci, President and CEO, will share the latest corporate updates at the Jefferies London Healthcare Conference this week.? ? We invite you to tune in to the live or archived presentation here: https://lnkd.in/e4eZQJnk? ? #JefferiesHealthcare #Biotechnology??

We are seeing steady advancement across our pipeline of clinical and preclinical programs and look forward to continued momentum as we head into 2025.?? ? Learn about our Q3 progress and anticipated plans for the rest of the year in our Q3 2024 financial press release: https://lnkd.in/eeNq9bmY ? $CADL #BiotechNews #ClinicalTrials?

This Lung Cancer Awareness Month we're highlighting our innovative approach to treating non-small cell lung cancer (NSCLC). Our investigational viral immunotherapy, CAN-2409, has shown promise in converting non-responders to immune checkpoint inhibitors (ICIs) into responders.? ? Learn more about our approach: https://lnkd.in/dGPghctu? ? #LungCancerAwareness #CancerResearch #ClinicalTrials #NSCLC?

Today, we're presenting our poster on CAN-3110's activity in melanoma models at #SITC24. Our findings support the potential expansion of CAN-3110 from high-grade glioma to #melanoma, both nestin-expressing solid tumors.? ? https://lnkd.in/e7AgfVmA ? #CancerResearch #Immunotherapy?? Society for Immunotherapy of Cancer (SITC)?

We're presenting preclinical results on the therapeutic potential of CAN-3110 in the Ras-Raf pathway altered #melanoma model at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. Our poster will showcase CAN-3110's potent antitumor activity and immune activation in preclinical melanoma models. Learn more: https://lnkd.in/e7AgfVmA #SITC24 #CancerResearch #Immunotherapy #Melanoma